Prevalence of Sarcopenic Obesity in COPD

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-100
SponsorIRCCS San Raffaele Roma

About this trial

The goal of this observational study is to the purpose is to apply of ESPEN/EASO criteria for the diagnosis of sarcopenic obesity and calculation of OS prevalence in a sample of COPD patients.

In addition, this study want to evaluate the impact of sarcopenic obesity on the respiratory function of COPD patients and the degree of severity of respiratory disease, assessed by spirometric examination; diaphragm thickness and excursion, by ultrasonographic study; performance, assessed by six-minute walk test (6-MWT); quality of life and degree of dyspnea (mMRC, Barthel dyspnea, S. George Respiratory Questionnaire); compliance and outcomes at the end of the respiratory rehabilitation course. Comparison with normal-weight patients with and without sarcopenia will help to better understand the clinical impact of sarcopenic obesity in this category of patients.

Eligibility criteria

Qualifiers

Patients aged > 40 years of either sex;

BMI >18.5

COPD diagnosis according to the GOLD [2021 Global initiative for chronic obstructive lung disease] classification in the stable stage;

Signing of informed consent after receiving all information about the study.

Disqualifiers

COPD not stabilized at the time of enrollment;

BMI < 18.5

presence of tracheostomy

uncontrolled hypertension (systolic blood pressure > 160 mmHg, diastolic > 100 mmHg);

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

236 Participants
are grouped into 3 trial groups

Sponsors and collaborators